Amended Statement of Ownership (sc 13g/a)
February 11 2021 - 06:07AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 1)*
Cancer
Genetics, Inc.
(Name
of Issuer)
Common
Stock, par value $0.0001 par value
(Title
of Class of Securities)
13739U203
(CUSIP
Number)
December
31, 2020
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this
Schedule is filed:
☐
Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a
prior cover page.
The
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the
Notes).
CUSIP
No. 13739U203 |
|
13G |
|
Page
2 of 9 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Ionic Ventures, LLC |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☐
(b) ☒ |
3. |
SEC
USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
California, United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
0
|
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
0
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
12. |
TYPE
OF REPORTING PERSON (see instructions)
OO |
CUSIP
No. 13739U203 |
|
13G |
|
Page
3 of 9 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Brendan O’Neil |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☐
(b) ☒ |
3. |
SEC
USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
0 |
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
0 |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
12. |
TYPE
OF REPORTING PERSON (see instructions)
IN |
CUSIP
No. 13739U203 |
|
13G |
|
Page
4 of 9 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Keith Coulston |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☐
(b) ☒ |
3. |
SEC
USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
0 |
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
0 |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
12. |
TYPE
OF REPORTING PERSON (see instructions)
IN |
CUSIP
No. 13739U203 |
|
13G |
|
Page
5 of 9 Pages |
Item
1(a). Name of Issuer:
Cancer
Genetics, Inc. (the “Issuer”)
Item
1(b). Address of Issuer’s Principal Executive
Offices:
The
Issuer’s principal executive offices are located at 201 Route 17
North, 2nd Floor, Rutherford, NJ 07070.
Item
2(a). Names of Persons Filing:
This
statement is filed by: |
|
|
|
(i) |
Ionic
Ventures LLC, a California limited liability company
(“Ionic”); |
|
|
|
(ii) |
Brendan
O’Neil (“Mr. O’Neil”); and |
|
|
|
(iii) |
Keith
Coulston (“Mr. Coulston”). |
The
foregoing persons are hereinafter sometimes individually referred
to as a “Reporting Person” and collectively referred to as the
“Reporting Persons”. Any disclosures herein with respect to persons
other than the Reporting Persons are made on information and belief
after making inquiry to the appropriate party.
The
Reporting Persons have entered into a Joint Filing Agreement, a
copy of which is filed with this Schedule 13G as Exhibit 1,
pursuant to which they have agreed to file this Schedule 13G
jointly in accordance with the provisions of Rule 13d-1(k) of the
Act.
The
filing of this statement should not be construed in and of itself
as an admission by any Reporting Person as to beneficial ownership
of the securities reported herein.
Item
2(b). Address of Principal Business Office or, if none,
Residence:
The
principal business address of each of the Reporting Persons is 3053
Fillmore St, Suite 256 San Francisco, CA 94123.
Item
2(c). Citizenship:
Ionic
is a limited liability company organized under the laws of
California. Each of Mr. O’Neil and Mr. Coulston is a citizen of the
United States.
Item
2(d). Title of Class of Securities:
The
title of the class of securities to which this statement relates is
the Common Stock of the Issuer, $0.0001 par value per share (the
“Common Stock”).
Item
2(e). CUSIP Number:
13739U203
CUSIP
No. 13739U203 |
|
13G |
|
Page
6 of 9 Pages |
Item
3. If This Statement is Filed Pursuant to §§240.13d-1(b) or
240.13d-2(b) or (c), Check Whether the Person Filing is
a:
Not
applicable.
Item
4. Ownership.
(a)
Amount Beneficially owned: |
|
|
|
|
● |
Ionic
– 0 |
|
|
|
|
● |
Mr.
O’Neil – 0 |
|
|
|
|
● |
Mr.
Coulston – 0 |
|
|
|
(b)
Percent of class: |
|
|
|
|
● |
Ionic
– 0% |
|
|
|
|
● |
Mr.
O’Neil – 0% |
|
|
|
|
● |
Mr.
Coulston – 0% |
|
|
|
(c)
Number of shares as to which the Report Person has: |
|
|
|
● |
Ionic |
|
|
|
|
|
(i) |
Sole
power to vote or direct the vote - 0 |
|
|
|
|
(ii) |
Shared
power to vote or direct the vote - 0 |
|
|
|
|
(iii) |
Sole
power to dispose or to direct the disposition of - 0 |
|
|
|
|
(iv) |
Shared
power to dispose or to direct the disposition of - 0 |
|
|
|
● |
Mr.
O’Neil |
|
|
|
|
(i) |
Sole
power to vote or direct the vote - 0 |
|
|
|
|
(ii) |
Shared
power to vote or direct the vote - 0 |
|
|
|
|
(iii) |
Sole
power to dispose or to direct the disposition of - 0 |
|
|
|
|
(iv) |
Shared
power to dispose or to direct the disposition of - 0 |
|
|
|
● |
Mr.
Coulston |
|
|
|
|
(i) |
Sole
power to vote or direct the vote - 0 |
|
|
|
|
(ii) |
Shared
power to vote or direct the vote - 0 |
|
(iii) |
Sole
power to dispose or to direct the disposition of - 0 |
|
|
|
|
(iv) |
Shared
power to dispose or to direct the disposition of - 0 |
Item
5. Ownership of Five Percent or Less of a Class.
If
this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following ☒.
Item
6. Ownership of More than Five Percent on Behalf of Another
Person.
Not
applicable.
CUSIP
No. 13739U203 |
|
13G |
|
Page
7 of 9 Pages |
Item
7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company.
Not
applicable.
Item
8. Identification and Classification of Members of the
Group.
Not
applicable.
Item
9. Notice of Dissolution of Group.
Not
applicable.
Item
10. Certification.
By
signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect, other
than activities solely in connection with a nomination under §
240.14a-11.
CUSIP
No. 13739U203 |
|
13G |
|
Page
8 of 9 Pages |
After
reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Date:
February 10, 2021 |
IONIC
VENTURES, LLC |
|
|
|
/s/
Keith Coulston |
|
Name:
Keith Coulston |
|
Title:
Partner |
|
|
|
/s/
Brendan O’Neil |
|
Brendan
O’Neil |
|
|
|
/s/
Keith Coulston |
|
Keith
Coulston |
CUSIP
No. 13739U203 |
|
13G |
|
Page
9 of 9 Pages |
EXHIBIT 1
JOINT
FILING AGREEMENT
PURSUANT
TO RULE 13d-1(k)
The
undersigned acknowledge and agree that the foregoing statement on
Schedule 13G is filed on behalf of each of the undersigned and that
all subsequent amendments to this statement on Schedule 13G shall
be filed on behalf of each of the undersigned without the necessity
of filing additional joint filing agreements. The undersigned
acknowledge that each shall be responsible for the timely filing of
such amendments, and for the completeness and accuracy of the
information concerning him or it contained herein and therein, but
shall not be responsible for the completeness and accuracy of the
information concerning the others, except to the extent that he or
it knows or has reason to believe that such information is
inaccurate. The undersigned hereby further agree that this Joint
Filing Agreement may be executed in any number of counterparts,
each of which when so executed shall be deemed to be an original,
but all of which counterparts shall together constitute one and the
same instrument.
Date:
February 10, 2021 |
IONIC
VENTURES, LLC |
|
|
|
/s/
Keith Coulston |
|
Name:
Keith Coulston |
|
Title:
Partner |
|
|
|
/s/
Brendan O’Neil |
|
Brendan
O’Neil |
|
|
|
/s/
Keith Coulston |
|
Keith
Coulston |
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2022 to Aug 2022
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2021 to Aug 2022